Title | Mapping the human genetic architecture of COVID-19 |
DOI | https://doi.org/10.1038/s41586-021-03767-x |
Method | Genome wide association study |
Curator 1 | fatima |
Curator 2 | admin |
Population | COVID-19-HGI |
Published | Yes |
| Variant detail | Description of Comparison | Gene | RSID | Association | Disease Status | MAF | Statistical Odds Ratio | Statistical P-value |
Variant | COVID-19 HGI_10490770 | Hospitalised vs Controls | LZTFL1, CXCR6, LOC107986083 | rs10490770 | Positive | Severe | 0.081 | 1.649 | 1.44e-73 |
Variant | COVID-19 HGI_10490771 | Critical vs Controls | LZTFL1, CXCR6, LOC107986083 | rs10490770 | Positive | Critical | 0.075 | 1.885 | 2.20e-61 |
Variant | COVID-19 HGI_rs10774671 | Hospitalised vs Controls | OAS1, OAS2, OAS3 | rs10774671 | Positive | Severe | 0.664 | 1.107 | 6.14e-10 |
Variant | COVID-19 HGI_rs10774671 | Critical vs Controls | OAS1, OAS2, OAS3 | rs10774671 | Positive | Critical | 0.652 | 1.2 | 4.08e-13 |
Variant | COVID-19 HGI_rs11918389 | Susceptibility vs Control | RPL24, CEP97, NXPE3, ZBTB11 | rs11918389 | Negative | Mild | 0.354 | 0.941 | 3.46e-15 |
Variant | COVID-19 HGI_rs13050728 | Hospitalised vs Controls | IFNAR2 | rs13050728 | Negative | Severe | 0.651 | 0.861 | 2.72e-20 |
Variant | COVID-19 HGI_rs13050728 | Critical vs Controls | IFNAR2 | rs13050728 | Negative | Critical | 0.652 | 0.819 | 1.05e-16 |
Variant | COVID-19 HGI_rs1819040 | Hospitalised vs Controls | KANSL1, ARHGAP27, PLEKHM1, LINC02210-CRHR1, CRHR1, SPPL2C, MAPT, STH, LRRC37A, ARL17B, LRRC37A2, ARL17A, NSF, WNT3 | rs1819040 | Negative | Severe | 0.186 | 0.879 | 1.83e-10 |
Variant | COVID-19 HGI_rs1886814 | Hospitalised vs Controls | FOXP4 | rs1886814 | Positive | Severe | 0.042 | 1.262 | 1.11e-09 |
Variant | COVID-19 HGI_rs2109069 | Hospitalised vs Controls | DPP9 | rs2109069 | Positive | Severe | 0.312 | 1.154 | 2.76e-17 |
Variant | COVID-19 HGI_rs2109069 | Critical vs Controls | DPP9 | rs2109069 | Positive | Critical | 0.316 | 1.26 | 9.68e-22 |
Variant | COVID-19 HGI_rs2271616 | Susceptibility vs Control | SLC6A20, CCR3, LOC107986082 | rs2271616 | Positive | Mild | 0.118 | 1.155 | 1.79e-34 |
Variant | COVID-19 HGI_rs4801778 | Susceptibility vs Control | PLEKHA4, PPP1R15A, TULP2, NUCB1, HSD17B14 | rs4801778 | Negative | Susceptibility | 0.18 | 0.946 | 1.18e-08 |
Variant | COVID-19 HGI_rs529565 | Susceptibility vs Control | ABO | rs529565 | Negative | Susceptibility | 0.651 | 0.905 | 1.45e-39 |
Variant | COVID-19 HGI_rs72711165 | Hospitalised vs Controls | TMEM65 | rs72711165 | Positive | Severe | 0.013 | 1.37 | 2.13e-09 |
Variant | COVID-19 HGI_rs74956615 | Hospitalised vs Controls | RAVER1, FDX2, ICAM1, ICAM4, ICAM5, ZGLP1, ICAM3, TYK2 | rs74956615 | Positive | Severe | 0.048 | 1.266 | 5.50e-10 |
Variant | COVID-19 HGI_rs74956615 | Critical vs Controls | RAVER1, FDX2, ICAM1, ICAM4, ICAM5, ZGLP1, ICAM3, TYK2 | rs74956615 | Positive | Critical | 0.048 | 1.434 | 9.71e-12 |
Variant | COVID-19 HGI_rs77534576 | Critical vs Controls | KAT7, TAC4, DLX3, FLJ45513 | rs77534576 | Positive | Critical | 0.033 | 1.446 | 4.37e-09 |